Pompe Disease Market Report 2026

Pompe Disease Market Overview

• Pompe Disease market size has reached to $1.8 billion in 2025 • Expected to grow to $2.49 billion in 2030 at a compound annual growth rate (CAGR) of 6.8% • Growth Driver: Surge In Healthcare Expenditure Propels Pompe Disease Market Growth • Market Trend: Advancing Investigational Therapies For Pompe Disease • North America was the largest region in 2025.

What Is Covered Under Pompe Disease Market?

Pompe disease is a genetic condition in which a complex sugar called glycogen accumulates in the body's cells. The situation is caused by a lack of an enzyme known as acid alfa glucosidase (GAA), which breaks down complex carbohydrates in the body. The main types of pompe disease are the classic infantile form, non-classic infantile form, late-onset form, and others. The classic infantile form of pompe disease is the most well-known, with significant heart dysfunction and obvious hypotonia beginning within a few months after birth. The various diagnosis includes blood test, genetic tests, prenatal tests, and other diagnoses. The treatment for pompe disease includes oral, parenteral, and others. The therapies for pompe disease are enzyme replacement therapy (ERT), substrate reduction therapy (SRT), gene therapy, and others that are used by hospitals or clinics, pharmaceuticals, researchers, and others.

What Is The Pompe Disease Market Growth Forecast?

The pompe disease market size is expected to see strong growth in the next few years. It will grow to $2.49 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rising investments in gene and cell therapies, increasing research on next-generation ERTs, expansion of personalized medicine approaches, growing access to rare disease diagnostics, increasing focus on early intervention strategies. Major trends in the forecast period include increasing adoption of enzyme replacement therapy, rising focus on early genetic screening, growing development of gene therapy approaches, expansion of specialized treatment centers, enhanced long-term disease management.

What Is The Driver Of The Pompe Disease Market?

The growing healthcare expenditure is expected to propel the growth of the Pompe disease market going forward. Healthcare expenditure refers to the financial resources allocated by governments, insurers, and private organizations to improve medical services, strengthen diagnostic capabilities, and expand treatment access. The demand for higher healthcare investment is increasing as health systems prioritize early detection, rare disease management, and improved patient outcomes. Increased spending supports wider adoption of enzyme replacement therapies and emerging innovations, enabling better care and improved quality of life for individuals with Pompe disease. For instance, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with the growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Therefore, the growing healthcare expenditure will drive the Pompe disease industry.

Key Players In The Global Pompe Disease Market

Major companies operating in the pompe disease market are Sanofi S.A., Genzyme Corporation, Amicus Therapeutics Inc., BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Valerion Therapeutics LLC, Protalix BioTherapeutics, AVROBIO Inc., Abeona Therapeutics Inc., Sangamo BioSciences Inc., Asklepios BioPharmaceutical Inc., Audentes Therapeutics Inc., Genethon, Akashi Therapeutics, M6P Therapeutics, Aro Biotherapeutics Company, Avidity Biosciences Inc., Maze Therapeutics Inc., Novartis AG, F. Hoffmann-La Roche AG, Spark Therapeutics Inc., REGENXBIO Inc.

Global Pompe Disease Market Trends and Insights

Major companies operating in the Pompe disease market are focusing on strategic partnerships to enhance product development, expand market reach, and improve animal health solutions. A strategic partnership typically refers to a collaborative relationship between two or more organizations where they combine their resources, expertise, and efforts to achieve common goals or objectives. For instance, in June 2024, Shionogi & Company, Limited, a Japanese pharmaceutical company, signed a global licensing deal with Maze Therapeutics, a US-based biotechnology company, for MZE001, an investigational oral drug targeting Pompe disease. Shionogi gains exclusive rights to MZE001 and its related intellectual property for an initial payment of $150 million, plus potential milestone and royalty payments. The agreement was finalized after the required 30-day review period under U.S. antitrust law (HSR Act).

What Are Latest Mergers And Acquisitions In The Pompe Disease Market?

In May 2024, Maze Therapeutics, a US-based biotechnology company that develops a Pompe disease drug candidate, partnered with Shionogi & Co., Ltd., to advance MZE001, an investigational first-in-class oral therapy for Pompe disease. The agreement grants Shionogi global rights to develop and commercialize MZE001, which is currently in Phase 1 clinical testing. Shionogi & Co., Ltd. is a Japan-based pharmaceutical company providing commercial drug development, manufacturing, and market-ready therapeutic solutions.

What Defines the Pompe Disease Market?

The pompe disease market includes revenues earned by entities by lumizyme, alglucosidase alfa, nexviazyme, and aval glucosidase alfa. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pompe Disease Market Report 2026?

The pompe disease market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pompe disease industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.